FDA Approves Anti-Epileptic Drug XCOPRI

December 5, 2019

FDA Approves Anti-Epileptic Drug XCOPRI

The FDA granted approval to SK Biopharmaceuticals, Co., Ltd. and its U.S. subsidiary SK Life Science, Inc. for XCOPRI (cenobamate tablets) as a treatment for partial-onset seizures in adult patients.This approval is the first time that a Korean pharmaceutical company has independently brought a compound from discovery to U.S. FDA approval. WIth our global footprint, Yourway is well positioned to support international clinical trials.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Schedule a Meeting

Global Clinical Supplies Group Asia Pacific Conference

March 11-13, 2026
Conrad Seoul Hotel, South Korea

Schedule a Meeting

Media

Articles

Just-in-Time or Plan Ahead? Mastering Logistics Strategies for Complex Clinical Trials

Open chat

Hello! How can I help you?